Deferred Tax Assets, Valuation Allowance of Akari Therapeutics Plc from 31 Dec 2014 to 31 Dec 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
Summary
Akari Therapeutics Plc quarterly Deferred Tax Assets, Valuation Allowance in USD history and change rate from 31 Dec 2014 to 31 Dec 2024.
  • Akari Therapeutics Plc Deferred Tax Assets, Valuation Allowance for the quarter ending 31 Dec 2024 was $60,340,000, a 43% increase year-over-year.
Source SEC data
View on sec.gov
Deferred Tax Assets, Valuation Allowance, Quarterly (USD)
Deferred Tax Assets, Valuation Allowance, YoY Quarterly Change (%)

Akari Therapeutics Plc Quarterly Deferred Tax Assets, Valuation Allowance (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q4 2024 $60,340,000 +$18,098,000 +43% 31 Dec 2024 10-K 15 Apr 2025 2024 FY
Q4 2023 $42,242,000 +$13,375,000 +46% 31 Dec 2023 10-K 15 Apr 2025 2024 FY
Q4 2022 $28,867,000 -$1,455,192 -4.8% 31 Dec 2022 8-K 06 Sep 2024
Q4 2021 $30,322,192 +$4,105,133 +16% 31 Dec 2021 20-F 01 May 2023 2022 FY
Q4 2020 $26,217,059 +$4,287,781 +20% 31 Dec 2020 20-F 16 May 2022 2021 FY
Q4 2019 $21,929,278 +$2,987,623 +16% 31 Dec 2019 20-F 21 Apr 2021 2020 FY
Q4 2018 $18,941,655 -$1,159,720 -5.8% 31 Dec 2018 20-F 31 Mar 2020 2019 FY
Q4 2017 $20,101,375 +$4,210,615 +26% 31 Dec 2017 20-F 23 Apr 2019 2018 FY
Q4 2016 $15,890,760 +$1,336,161 +9.2% 31 Dec 2016 20-F 18 Jul 2018 2017 FY
Q4 2015 $14,554,599 +$12,147,267 +505% 31 Dec 2015 20-F 31 Mar 2017 2016 FY
Q4 2014 $2,407,332 31 Dec 2014 10-K 23 Mar 2016 2015 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.